<?xml version='1.0' encoding='utf-8'?>
<document id="24937160"><sentence text="Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information." /><sentence text="1" /><sentence text=" Recently, the Food and Drug Administration (FDA) and European Medicines Agency have shown decision trees to determine whether a drug candidate is an inhibitor of P-glycoprotein (P-gp)" /><sentence text=" However, there has been no clear information on whether P-gp inhibition can be significant in clinical drug-drug interactions (DDIs)" /><sentence text=" The purpose of this study was to confirm the effect of P-gp inhibition through comprehensive analysis of the clinical DDI studies" /><sentence text=" 2" /><sentence text=" Clinical information on P-gp inhibition was collected using the University of Washington Metabolism and Transport Drug Interaction Databaseâ„¢" /><sentence text=" The risks of P-gp inhibition-related DDI were qualitatively evaluated in terms of the contribution of CYP3A inhibition" /><sentence text=" The degrees of DDI risk were categorized using the area under the plasma concentration-time curve increase ratio (AUCR), according to the FDA DDI criteria" /><sentence text=" 3" /><sentence text=" When both P-gp and CYP3A were inhibited, the DDI risks were potent in 25% of the studies" /><sentence text=" When CYP3A inhibition did not contribute to the DDI, no study was categorized as potent DDI risk, and the detailed analysis revealed that AUCRs were basically &lt;3" /><sentence text="0" /><sentence text=" The DDI risk caused by P-gp inhibition solely would be limited, although the use of P-gp substrates with narrow therapeutic range should be carefully controlled" /><sentence text="" /></document>